调强放疗单用与联合化疗对不同亚组鼻咽癌远期疗效的影响  

Long-term efficacy of IMRT alone,combination with chemotherapy on different subgroups of NPC

作　　者：刘珍[1] 苏小岩[1] 胡艳[1] 周福祥[2] 

机构地区：[1]荆州市第一人民医院肿瘤科,湖北荆州434000 [2]武汉大学中南医院放化疗科,湖北武汉430000

出　　处：《热带医学杂志》2016年第5期654-657,共4页Journal of Tropical Medicine

摘　　要：目的探讨调强放疗单用、联合化疗对不同亚组鼻咽癌远期疗效的影响。方法选择鼻咽癌患者146例为研究对象,根据治疗方法不同随机分为观察组和对照组,观察组患者接受调强放疗联合化疗,对照组患者仅接受调强放疗,随访两组患者的生存时间,检测血清血管内皮生长因子(VEGF)、血小板衍生生长因子(PDGF)含量。结果Ⅰ期、Ⅱa期、Ⅱb期鼻咽癌亚组中,观察组和对照组患者的无进展生存时间、总生存时间、以及血清VEGF、PDGF含量差异无统计学意义(P>0.05);Ⅲ期、Ⅳa期、Ⅳb期鼻咽癌亚组中,观察组患者的无进展生存时间和总生存时间均明显长于对照组(P<0.05),血清VEGF、PDGF含量明显低于对照组(P<0.05)。结论调强放疗联合化疗治疗早期鼻咽癌的疗效与单纯调强放疗相当,治疗晚期鼻咽癌的疗效优于单纯调强放疗,能够延长生存时间,降低血管新生因子含量。Objective To study the long-term efficacy of IMRT alone, combination with chemotherapy on different subgroups of NPC. Methods 146 cases NPC patients were randomly divided into two groups according to different treatment methods, the observation group patients received IMRT combined with chemotherapy, the control group patients received only IMRT. Survival time, serum VEGF, PDGF levels were detected. Results In stage I, phase Ⅱa and NPCⅡb subgroups, progression-free survival time, overall survival and serum VEGF, PDGF levels were not different from those of control group（t=0.098~0.281, P〉0.05）, in stage III, phase Ⅳa, and phase Ⅳb NPC subgroups, progressionfree survival time, overall survival time of observation group were longer than those of the control group（t=5.228~6.991,P 〈0.05）, and serum VEGF, PDGF contents were less than those of the control group（t =5.592 ~7.283,P 〈0.05）.Conclusion Efficacy of IMRT combined with chemotherapy in the treatment of early nasopharyngeal was not better than IMRT treatment alone. Efficacy of IMRT combined with chemotherapy in the treatment of advanced nasopharyngeal carcinoma was better than IMRT treatment alone, it can prolong the survival time and reduce angiogenesis factors levels.

关 键 词：鼻咽癌 调强放疗 化疗 远期预后 血管新生 

分 类 号：R739.6[医药卫生—肿瘤]